| Latest Forum Topics / QT Vascular |
 Post Reply
|
|
QT Vascular Going BIG
|
|||||
|
dingbat
Veteran |
03-May-2014 18:15
|
||||
|
x 0
x 0 Alert Admin |
Why EDB see potential in this patented catheter PLEASANTON, Calif., and SINGAPORE, Feb. 19, 2014 /PRNewswire/ -- TriReme Medical LLC, a subsidiary of Singapore based QT Vascular Ltd., announced today that it has signed a broad distribution agreement with Cordis Corporation for the exclusive distribution of its unique Chocolate® PTA Balloon Angioplasty Catheter, with an option for additional TriReme portfolio products. This agreement will expand TriReme' s commercial footprint and allow the company to focus on its promising development pipeline. " Cordis has an unparalleled track record in creating and building new and innovative product categories that have dramatically changed and improved clinical practice. We are honored to partner with Cordis and look forward to our collaboration," said Dr. Eitan Konstantino, President and CEO of TriReme. The Chocolate® PTA Balloon Catheter, approved in the U.S. in December 2011, is a unique PTA balloon that is designed to allow for atraumatic dilatation in treating peripheral artery disease (PAD). The Chocolate® PTA Balloon Catheter is indicated for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries. Not for use in the coronary or cerebral vasculature. Its unique nitinol constraining structure creates uniform " pillows" that make contact with the vessel and " valleys" that allow for plaque modification and are designed to relieve stress upon inflation. Data from the first 350 patients in the CHOCOLATE® BAR Registry were recently presented at the 2014 Leipzig Interventional Course (LINC) earlier this month. In this all-comers study that included many patients suffering from advanced atherosclerotic disease in their legs and patients at high risk of amputation (Rutherford 5 and 6, total occlusions, long and calcified lesions), the use of the Chocolate® PTA Balloon Catheter was associated with high rates of treatment success and limb preservation and very low rates of dissections and bail-out stenting. " We are delighted to see TriReme gain this level of global recognition," stated Mr. Michael Kleine, board member of QT Vascular and former CEO of Biosensors International. " TriReme management has been building a valuable business by driving strong market adoption for its products backed with excellent clinical data." About Peripheral Arterial Disease Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide.1 About TriReme Medical, LLC TriReme, a subsidiary of Singapore based QT Vascular Ltd., is an emerging leader in the development and commercialization of next generation minimally invasive devices for the treatment of complex arterial disease. The company is focused on the US and the emerging Asian markets. 1. " Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet. SOURCE TriReme Medical, LLC |
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
03-May-2014 16:51
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
it is really an unknown whether this coy can survive in the small market against other big players. It has been bleeding for the last 3.75 years and how likely is it to continue bleeding for the next 1-2 years? My personal view: very likely since it it not like they have something no one else has and see my point in " Use of Proceeds" Proepsctus, page 57, Use of proceeds, $5mil for Commercial expansion includes marketing activities, expenses incurred in entering into further supplier and distributorship agreements, market expansion activities and costs of our sales force They spent $6mil on this in 9mth FY13 (against a revenue of $3mil!!!! = spent $2 dollar to earn $1 dollar). $5mil enough to last how long. Not stepping up their marketing effort? Why. Their existing product have not edge over others? Difficult to sell? I don' t know. $15mil for Development of new products and product enhancements. This one simple means until they got something and something that can sell, there should be no reveune from this $15mil. Their R& D expenses are about on average $6mil for FY 2011 and FY 2012 but 9 mths into FY13, only $2mil. Spent too much on marketing and has to scarifice R& D? Anyway, that $15mil can last for another 2 years. $30mil for General working capital purposes Bottomline: I think their existing products are not doing so well (why US sale dropped so much just after one year??? The existing customers didn' t contiune or want to continee the orders?) and they are in search of new products. Obviously the highest. Why? Still need to pay salaries (maybe also bonus?), pay rents, pay utilities while waiting for their existing products to fly (if they do) and new products to emerge (if they do) and fly (if they do). Also look at propsectus page 75. Almost all shareholders' s average price are below 28cts and some very much below. They are locked-up for six-month to prevent a major sell-down on day 1 as usual but this thing works both ways. It may be to so-call protect new invetors but extend your horizon to six months later many people will have forgotten that the lock-up has expired it then present the opportunties for these shareholders to start offloading their holdings. Maybe not so for funds but great incentives for those pre-IPO investors. If you are them, will you hold or sell? Well they maybe in for the long haul. Who knows? When it open high at 34cts on first day I am really puzzle. But they can support the price at a resaonable level on the basis that it is cheap has " potential" and should worth, the real show may only begins six months later. Not shooting this one down but just rasing some of my observation and thoughts. Maybe this coy has some super-duper products that is about to change the World. Who knows? it may fly tomorrow but until it shows some creditable results, any bet now is obviously risky. DYDD. 
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
singaporegal
Supreme |
03-May-2014 16:18
Yells: "Female TA nut" |
||||
|
x 0
x 0 Alert Admin |
We have to be extra careful of penny stocks. Very volatile. |
||||
| Useful To Me Not Useful To Me | |||||
|
dingbat
Veteran |
03-May-2014 14:58
|
||||
|
x 0
x 0 Alert Admin |
Source is Singapore IPOs blog spot
|
||||
| Useful To Me Not Useful To Me | |||||
|
dingbat
Veteran |
03-May-2014 14:56
|
||||
|
x 0
x 0 Alert Admin |
My previous post was sourced from Singapore IPOs blog spot. For some reason couldn' t paste the link. Listed first 3 days and kenna selldown to near placement price. If BB' s don' t support their counter, bodes badly for QT since plenty of selling and not enough buying from the kickoff.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Peterngchinheng
Senior |
03-May-2014 14:13
|
||||
|
x 0
x 0 Alert Admin |
My colleague bought 50lot for 34.5cent at 1st day.... After calculate, 2k loss oh.....
|
||||
| Useful To Me Not Useful To Me | |||||
|
singaporegal
Supreme |
03-May-2014 13:54
Yells: "Female TA nut" |
||||
|
x 0
x 0 Alert Admin |
Medical stocks |
||||
| Useful To Me Not Useful To Me | |||||
|
Markie
Senior |
02-May-2014 17:28
|
||||
|
x 0
x 0 Alert Admin |
whose selling?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
spamalot
Member |
02-May-2014 17:21
|
||||
|
x 0
x 0 Alert Admin |
Trying hard to claw back from the beating. BBs too relak.... |
||||
| Useful To Me Not Useful To Me | |||||
|
dingbat
Veteran |
02-May-2014 13:40
|
||||
|
x 0
x 0 Alert Admin |
The placement results for QT Vascular throw up an interesting surprise. In addition to the substantial shareholders who continue to support the company such as EDB and Johnson and Johnson, there is a new shareholder just below 5%, Asdew. Asdew Acquisition - Alan Wang took a very substantial stake in the Company. He is the same person behind very Hankore placement before it more than doubled from 5c. There is another investor called Havenport which I have previously blog about, founded by the team at Legg Mason. Let' s see if the 2 new substantial shareholders can perform some magic to the counter
|
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
29-Apr-2014 16:46
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
They seems to be into a very specialised medical product. This implied a small market so will need a respectable margin. However, from its prospectus, it mentioned that it is competing with some big name resulting in low margin (supposedlyto win sale). It also need to spend a lot on its marketing effort ($$$). Has been loss making in the last few years I believe. Sale in Europe is up but growth is low. Sale in US have dropped after a one poeak in 2012 may implied uptake of their product is weak. Started on Aisan market but sale is still low. It is a big unknown if they can made it let alone make it big. ofc high risk high return. Who knows. Perhaps best to see how they perform in the next few quarters first. DYDD.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Pauperman
Master |
29-Apr-2014 16:23
|
||||
|
x 0
x 0 Alert Admin |
Cornered counter frm the beginning. Will it move like Talkmed? |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Pauperman
Master |
29-Apr-2014 16:03
|
||||
|
x 0
x 0 Alert Admin |
IPO on 29 April 2014 with 755,882,836 ordinary shares issued. The Group is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The Group collaborates with industry specialists and physicians who are key opinion leaders to develop and offer physicians and patients new and differentiated devices to improve outcomes in complex peripheral and coronary interventions. |
||||
| Useful To Me Not Useful To Me | |||||